Etretinate

Etretinate
Etretinate
Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a601010
Pregnancy cat.  ?
Legal status  ?
Routes Oral
Pharmacokinetic data
Half-life 120 days
Identifiers
CAS number 54350-48-0 N
ATC code D05BB01
PubChem CID 5282375
DrugBank APRD00966
ChemSpider 4445538 YesY
UNII 65M2UDR9AG YesY
KEGG D00316 YesY
ChEBI CHEBI:4913 YesY
ChEMBL CHEMBL464 YesY
Chemical data
Formula C23H30O3 
Mol. mass 354.483 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.

Contents

Properties

Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days, which make dosing difficult.

Etretinate is an aromatic retinoid, and therefore highly lipophilic. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy.

Etretinate has been replaced by acitretin, a safer metabolite of etretinate.

Precautions

  • Etretinate is a teratogen, and may cause birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.
  • Etretinate should be avoided in children, as it may interfere with bone growth.
  • If a patient has ever taken etretinate, he or she is not eligible to donate blood, due to the risk of birth defects.[1]

Side effects

References

  1. ^ UK Blood Transfusion and Tissue Transplantation Services[1]